Minretumomab

Summary

Minretumomab (CHEMBL2108796) is a phase-3 clinical-stage antibody; indicated across 7 conditions including colorectal adenocarcinoma and exocrine pancreatic carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 7 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108796
Name	Minretumomab
Type	Antibody
Max phase	3

Also known as: Cc-49, CC49, MAB-CC49, Minretumomab, MOAB CC49, MINRETUMOMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
colorectal adenocarcinoma	1	MONDO:0005008	EFO:0000365
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618
rectal cancer	1	MONDO:0006519	EFO:1000657
gastric neoplasm	1	MONDO:0021085	MONDO:0001056
colonic neoplasm	1	MONDO:0005401	MONDO:0021063
colorectal neoplasm	1	MONDO:0005335	MONDO:0005575

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).